Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

Uptake of Adtralza, Rinvoq and Cibinqo for treating atopic dermatitis will be slow in the UK following NICE’s rejection, says GlobalData

Based on the uncertainty relating to the comparison of efficacies of Leo Pharma’s anti-IL-13, Adtralza/Adbry (tralokinumab); AbbVie’s oral Janus kinase (JAK) 1 inhibitor, Rinvoq (upadacitinib); and Pfizer’s oral JAK 1 inhibitor, Cibinqo (abrocitinib) to standard treatments, the UK’s National Institute for Health and Care Excellence (NICE) is not recommending these agents for the treatment of […]
Read more

Neuroimmunology drug development has exploded over the last decade, growing into a dynamic, high-value space, says GlobalData

Over the last decade, the role of the immune system in the etiology and pathophysiology of neurological diseases has steadily gained clarity, says GlobalData. The leading data and analytics company notes that the development of neuroimmunology drugs* has exploded as a result, with the top 20 neuroimmunology products being worth $20.1 billion in 2020 and […]
Read more

Mavacamten estimated sales just shy of $1 billion if approved for common cardiomyopathy subtype, says GlobalData

Bristol Myers Squibb’s mavacamten will stand rather unchallenged in the hypertrophic cardiomyopathy (HCM) market, achieving around $958 million in sales by 2025, according to GlobalData, a leading data and analytics company. Sarah Bundra, Pharmaceutical Analyst at GlobalData, comments: “Mavacamten will be the first drug to specifically target obstructive HCM, which is a common form of cardiomyopathy. […]
Read more

Digital diabetes care support on rise in India, observes GlobalData

Diabetes has reached epidemic proportions over the last three decades and India continues to have the second-largest number of adults with diabetes worldwide, after China. Consequently, lifestyle management is a  crucial step in improving  patient outcomes and metabolic parameters associated with the disease. In this context, various pharmaceutical companies and healthtech companies are offering personalized […]
Read more

Current treatments for diabetic complication macular edema still not effective enough despite influx of new drugs, says GlobalData

While there have been several significant steps forward when it comes to treating diabetes complication diabetic macular edema (DME) this year, current therapies are still not effective enough, according to GlobalData. The leading data and analytics company notes that not only is there still a surplus of unmet needs, but current therapies still have quite […]
Read more

Russian companies involved in innovator drug licensing agreement remains low, says GlobalData

Over the past five years, very few licensing agreements for innovator drugs have involved Russian biopharmaceutical companies where the majority involve drugs that are marketed, says GlobalData. The leading data and analytics company notes that these licensing agreements include the commercialization, manufacturing, and/or distribution of innovator drugs involving Russian biopharmaceutical companies from 2017 to 2021. […]
Read more

Axsome Therapeutics’ migraine treatment AXS-07 faces many hurdles before FDA approval, says GlobalData

Axsome Therapeutics expects to receive a complete response letter (CRL) from the FDA due to the recently revealed chemistry, manufacturing, and control (CMS) issues identified during the FDA’s review of its new drug application for AXS-07 (rizatriptan and meloxicam), for the acute treatment of migraines. According to GlobalData’s report, ‘Migraine Drug Market Size, Share & Trends Analysis […]
Read more

Mavacamten will achieve a dominant share of hypertrophic cardiomyopathy market as it significantly improves patients’ quality of life, says GlobalData

At the 71st annual American College of Cardiology (ACC) 2022 meeting, results were presented from MAVA-LTE, the ongoing five-year study of mavacamten in obstructive hypertrophic cardiomyopathy (oHCM). Based on these results, mavacamten will likely dominate the oHCM market as the first-in-class cardiac myosin inhibitor and rapidly steal market share from the non-specific therapies that are […]
Read more

Nuvaxovid COVID-19 vaccine approval in Japan helps Novavax further expand in Asia, says GlobalData

American biotech company Novavax, together with Japan-based Takeda, has secured Japanese Ministry of Health, Labour and Welfare (MHLW) approval for its recombinant, adjuvanted virus-like particle COVID-19 vaccine Nuvaxovid. With this move, Novavax continues its expansion in Asia through local partners, says GlobalData, a leading data and analytics company. According to GlobalData’s Pharma Intelligence Center, Japan […]
Read more

Innovent IBI310 and sintilimab combination will improve access to cervical cancer treatment in China, says GlobalData

The China National Medical Products Administration (NMPA) has recently granted breakthrough therapy (BTD) designation to Innovent Biologics’ (Innovent) IBI310 in combination with sintilimab to treat patients with recurrent or metastatic cervical cancer. The move will further improve access to targeted treatment options in the current treatment paradigm of cervical cancer, says GlobalData, a leading data […]
Read more
1 … 48 49 50 51 52 … 110